Event

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle: PREFER – an IMI Project

Add to:

In our 1-hour webinar on the 12 of July 2017 (4:30pm CET, 3:30pm BST, 10:30am EST) we will have a presentation by Conny Berlin and Rachael DiSantostefano

By Conny Berlin and Rachael DiSantostefano

In our 1-hour webinar on the 12 of July 2017 (4:30pm CET, 3:30pm BST, 10:30am EST) we will have a presentation by Conny Berlin who is the industry project leader of the public-private IMI PREFER project and Rachael DiSantostefano, a task co-leader on the IMI PREFER project.  

Abstract

The main objective of the IMI PREFER project is to strengthen patient-centric decision making throughout the life cycle of medicinal products by developing evidence-based recommendations to guide industry, Regulatory Authorities, HTA bodies, reimbursement agencies, academia, and health care professionals on how and when patient-preference studies should be performed and the results used to support and inform decision making.

While over the last years all stakeholders gained experience individually how to engage patients for decision making this project aims to bring all stakeholders together taking a structured approach to determine their needs, expectations, and concerns regarding the use of patient-preference information and methodologies for patient-preference elicitation. 

Methodologies for patient value elicitation are available and have been used frequently in market research, in health economics and outcomes research to substantiate real-life evidence. Further structured research has been done in projects like IMI PROTECT but there is no systematic use of these methodologies in the regulatory licensing processes yet. 

The presentation will address 

  • Objective of PREFER
  • Changing environment
  • Patient preference study example
  • PREFER participants
  • PREFER project approach & status

About the Presenters

Conny Berlin, Global Head Quantitative Safety & Epidemiology, 
Novartis International AG
 


Conny Berlin

Conny Berlin leads the Quantitative Safety & Epidemiology group at Novartis International AG. She holds a degree in mathematics from the University of Rostock, Germany and has more than 25 years of experience within the pharmaceutical industry.

Conny Berlin has a profound knowledge of quantitative methodology as applied to clinical and observational data and to spontaneous reports to respond to safety and benefit-risk questions during drug development and post-approval.

Conny Berlin is a member of the company’s internal Medical Safety Review Board and of the Real World Evidence Leadership Team.

She is well experienced in managing projects, leading and coordinating interdisciplinary teams. Conny Berlin is the industry project leader of the public-private IMI PREFER project.

 Relevant references 

  • Esther W. de Bekker-Grob, Conny Berlin et al. Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project. Patient: Editorial
  • Participant of the CIOMS working group X on "Evidence Synthesis and Meta-Analysis for Drug Safety"; report published in 2016
  • Berlin C, Blanch C et al. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. Pharmacoepidemiology and Drug Safety. 2011: 622-630

 

Rachael DiSantostefano, PhD, MS is a Director, Benefit-Risk in Epidemiology at Janssen R&D

DiSantostefano_Rachael-2013_p57 medium

Rachael L. DiSantostefano has nearly 25 years of pharmaceutical research experience across the quantitative disciplines of epidemiology, biostatistics, and health outcomes.  She is currently responsible for guiding clinical teams in structured benefit-risk assessment, including the use of both qualitative and quantitative methods.   She received her PhD in Health Policy and her Master’s degree in Biostatistics at the University of North Carolina Gillings School of Global Public Health.  Prior to joining Janssen in 2015, she was an epidemiologist at another pharmaceutical company for 10 years, where she evaluated medication safety and contributed to benefit-risk assessment in regulatory submissions and at FDA Advisory Committee meetings.  She is currently active as a task co-leader on the IMI PREFER project and an active member of the Benefit-Risk Assessment Communication and Evaluation Special Interest Group (BRACE-SIG) within the International Society for Pharmacoepidemiology.

To access the recording, please visit the Video-on-Demand Library.

Upcoming Events

Latest Jobs